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ABSTRACT
Orthodontic tooth movement involves activation of osteoblasts and osteoclasts in
response to mechanical forces. Extracellular nucleotides, released in response to mechanical
stimuli, signal through P2 receptors in osteoblasts. P2X7 receptors are ATP-gated cation
channels implicated in mechanotransduction in bone. Corticosteroids such as dexamethasone
exhibit anti-inflammatory effects and their chronic use has been linked to serious side-effects
such as osteoporosis. We investigated gene expression following P2X7 receptor activation
with benzoylbenzoyl-ATP (P2X7 receptor agonist) in osteoblast precursor cells in the
presence or absence of dexamethasone. We hypothesized that dexamethasone inhibits the
ability of ATP to stimulate the expression of anabolic (bone forming) genes in osteoblasts.
We showed that benzoylbenzoyl-ATP stimulation of Ptgs2 and Dmp1 expression is indeed
inhibited by dexamethasone. Thus, intracellular events following activation of P2X7 may be
important in regulating osteoblast differentiation, maturation and eventual bone formation
during orthodontic tooth movement and dexamethasone may adversely affect these
processes.
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INTRODUCTION
1

Bone Physiology and Orthodontic Tooth Movement

Orthodontic tooth movement (OTM) is made possible by the complex interaction
between applied force and biologic response of the bone tissues. Understanding of the
intricate mechanisms by which mechanical stimuli are transformed into biologic
responses will aid in developing protocols for optimizing orthodontic tooth movement.
Tooth movement is accomplished by a coordinated activity of cells residing in the
periodontal ligament (PDL), circulating blood, and the surrounding bone (Figure 1). The
pressure-tension theory, the classic theory of OTM, states that chemical signals act as the
stimulus for cellular differentiation, resulting in bone remodeling and ultimately tooth
movement (Krishnan and Davidovitch, 2006; Schwarz, 1932). Sustained pressure causes
the tooth to shift within the PDL space, compressing the ligament on the pressure side
and stretching it on the tension side. This leads to fluid expression, as well as decreased
perfusion and hypoxia on the compression side while blood flow is maintained or
increased on the tension side (Khouw and Goldhaber, 1970).
The combined effect of mechanical stimulus and alterations in the blood flow and oxygen
levels create changes in the chemical environment resulting in the release of cytokines,
prostaglandins, growth factors and other chemical messengers within a few hours.
Animal experiments have revealed that within four hours of sustained force application
there is an increase in the nucleotide cyclic adenosine monophosphate (cAMP)
(Davidovitch et al., 1972). cAMP acts as a cytosolic second messenger, regulating
cellular functions such as differentiation of the local cells in the PDL with the capacity to
differentiate to form osteoclasts (bone removing cells) and osteoblasts (bone forming
cells) (Roberts, 1989). Studies have also shown that important mediators of cellular
response such as prostaglandin, interleukin-1 beta (IL-1) and nitric oxide (NO) levels
increase within the PDL (Krishnan and Davidovitch, 2006). Furthermore, Kang and
colleagues have shown that focal adhesion kinase (FAK) may act as the mechanoreceptor
in PDL cells and mediate PGE2 release (Kang et al., 2010).
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Figure 1. Biological basis of orthodontic tooth movement as explained by the
pressure-tension theory
Upon orthodontic force application, areas of pressure and tension are created as indicated
in the schematic. OTM can be explained by two-fold. 1) The PDL is compressed in the
pressure side and stretched in the tension side. The mechanical effects on cells of the
PDL cause them to release of cytokines, prostaglandins, and other chemical messengers.
2) The change in the PDL space alters the blood flow - it is decreased on compression
side and maintained or increased on the tension side. This can create changes in the
oxygen levels which then stimulates the release of other chemical messengers. These
factors then directly or indirectly stimulate cellular differentiation and activity. Cascade
of signaling events eventually lead to activation of osteoclasts on the pressure side
leading to bone resorption while osteoblasts form on the tension side to lay down newly
formed bone. (Figure adapted from www.askanorthodontist.com)
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Once differentiated, osteoclasts must remove bone on the compressed side of the PDL
while osteoblasts form new bone on the tension side for tooth movement to occur (Figure
1). The cellular activity in the bone surrounding the teeth during orthodontic tooth
movement is similar to the cellular activity involved in physiological bone remodeling.
1.1

Bone Structure and Function

Bone is a highly specialized and complex connective tissue that constitutes the skeleton.
It is lightweight yet strong and serves multiple functions. Bone supports and protects vital
organs, provides mechanical stability for body posture, serves as a site for muscle
attachment to support locomotion and is involved in the regulation of calcium and
phosphate mineral homeostasis (Baron, 2003). In addition, it serves as the primary site of
hematopoiesis as it supplies a source of hematopoietic and mesenchymal stem cells
(Clarke, 2008).
Bone is composed of a mineralized extracellular matrix containing both organic and
inorganic components. The organic portion of bone is primarily composed of collagen
type I and make up approximately 35% of bone mass. Type 1 collagen is an elastic
protein that provides bone with its tensile strength and flexibility and hence fracture
resistance (Baron, 2003). Non-collagenous proteins, such as bone sialoprotein (BSP),
osteocalcin (OCN), and osteopontin (OPN), are also present and are thought to regulate
the mineralization process (Clarke, 2008). A variety of cells including osteoblasts and
osteoclasts also make up a small portion of the organic phase. The inorganic components
of bone composes 65% of bone mass and consist of hydroxyapatite crystals
[Ca10(PO4)6(OH)2] (Hadjidakis and Androulakis, 2006). These crystals pack tightly
around collagen in the extracellular matrix, contributing to the hardness and resistance to
compressive loading giving bone its rigidity (Clarke, 2008)
The skeleton is composed of two types of bones: an axial skeleton which includes the
vertebrae, pelvis, and other flat bones such as the skull and sternum, and an appendicular
skeleton which includes all of the long bones (Baron, 2003). Long bones are most bones
in the limbs and include the humerus, radius, ulna, femur, tibia and fibula. They are
divided into three parts: the epiphysis, metaphysis and diaphysis (Clarke, 2008). The

4

epiphysis is the portion of the long bone at either end and develops from a center of
ossification. It is separated from the rest of the bone by a layer of growth cartilage known
as the “physis”. The metaphysis is the zone between the physis and the central portion of
the long bone shaft known as the diaphysis (Clarke, 2008).
Anatomically, bone is organized into an external layer of cortical (dense or compact)
bone, an internal network of trabecular (spongy or cancellous) bone and bone marrow
that resides within the trabecular spaces (Clarke, 2008). The epiphyses and metaphyses
are comprised of a trabecular network, while the diaphysis is made of dense compact
bone.
Bone is in contact with the soft tissues along two surfaces: an external surface (the
periosteal surface) and an internal surface (the endosteal surface). These surfaces are
lined with osteogenic cells along the periosteum and the endosteum, respectively (Baron,
2003).
Bone is formed by a process referred to as ossification. During the fetal stage, this occurs
by two processes: intramembranous ossification and endochondral ossification (Baron,
2003). Intramembranous ossification involves the formation of bone from connective
tissues such as the mesenchyme whereas in endochondral ossification, bone is formed
from cartilage (Clarke, 2008). Intramembranous ossification mainly occurs in the flat
bones of the skull and also occurs in the mandible, maxilla and clavicle. Endochondral
ossification occurs in the long bones and other bones in the body (Baron, 2003; Clarke,
2008).
The alveolar processes of the maxilla and the mandible provide the housing for the
dentition. The maxillae consist of two maxilla bones forming the upper jaw and palate of
the mouth. It develops entirely by intramembranous ossification and is thought to be
ossified from a center of mesenchymal condensation in the maxillary process that appear
during the sixth week of prenatal development (Proffit, 2012). Postnatal growth of the
maxilla occurs by apposition of bone at sutures that connect maxilla to cranium and
cranial base as well as by surface remodeling. The body of the mandible develops from
the condensation of mesenchyme just lateral to Meckel’s cartilage and proceeds entirely
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by intramembranous bone formation (Proffit, 2012). The condylar cartilage initially
develops as a secondary cartilage and fuses with the developing mandibular ramus in the
early fetal stages. Both endochondral and intramembranous ossification are important in
the growth of the mandible. The surface of the mandibular condyle is covered by
cartilage where endochondral changes occur. The rest of the mandible are formed and
grows by intramembranous ossification (Proffit, 2012).
1.2

Bone Cells and Their Functions

Three major cell-types are found within bone: the bone-resorbing osteoclast, the boneforming osteoblast and the mechanosensitive osteocyte (terminally differentiated
osteoblast) (Baron, 2003). Skeletal development and bone remodelling depend on the
communication among the bone cells and the coordinated activity of osteoblasts and
osteoclasts referred to as “coupling” (Clarke, 2008).
1.2.1

Osteoblasts

Cells of the osteoblast lineage develop from mesenchymal progenitor cells residing in the
bone marrow and the periosteum that also give rise to other cell-types including
chondrocytes, adipocytes, and fibroblasts (Harada and Rodan, 2003; Minguell et al.,
2001; Robling et al., 2006). The major function of mature osteoblasts is to synthesize and
secrete osteoid, the organic phase of the bone matrix, and regulate its mineralization
(Clarke, 2008). Osteoblast differentiation is characterized by lineage commitment,
proliferation, maturation and matrix mineralization. It is regulated by a number of
systemic hormones and local factors such as insulin-like growth factors and bone
morphogenetic proteins (BMPs). Osteoblast activity is regulated in an autocrine/paracrine
manner by these factors whose receptors can be found on osteoblasts (Baron, 2003).
In the last few decades, extensive work has gone into studying osteoblastogenesis from
mesenchymal progenitors to a mature bone-forming cell, and the involvement of a
number of key transcription factors and transcriptional co-activators have been
discovered. These factors function at specific times during osteoblast differentiation and
their expression defines the different stages of the osteoblast lineage.
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First, the chondrocyte master transcription factor sex-determining region Y (SRY)-box 9
(SOX9) is up-regulated in the mesenchymal progenitors that give rise to either
chondrocytes or osteoblasts (Akiyama et al., 2005). The osteoblast master transcription
factor runt-related transcription factor 2 (RUNX2) is then expressed and push the
proliferating precursor cells to the osteoblast lineage resulting in the formation of
osteochondroprogenitors. Subsequent downregulation of SOX9 gives rise to RUNX2positive osteoprogenitors. (Bendall and Abate-Shen, 2000; Ducy et al., 1997; Robling et
al., 2006). At this stage, RUNX2 further mediates expression of osteoblast-specific genes,
including collagen type I (COL1) and alkaline phosphatase (ALP), and the upregulation
of Osterix (OSX), a second osteoblast master transcription factor (Nishio et al., 2006). In
turn, OSX regulates expression of COL1 and bone sialoprotein (BSP) and, together with
RUNX2, promotes formation of the preosteoblast also known as immature osteoblast.
Further differentiation of the preosteoblast into a mature osteoblast requires the
expression of RUNX2, OSX and the canonical Wnt signaling pathway (β-catenin,
TCG/LEF1) (Ducy et al., 1997; Glass et al., 2005; Nakashima et al., 2002). The
transcription factor ATF-4 also plays an important role in the later stages of osteoblast
differentiation. In summary, ATF-4, OSX, and RUNX2 are all required for osteoblast
differentiation. In addition, the canonical Wnt transcriptional coactivator β-catenin is also
necessary at all stages of osteoblast differentiation.
Aside from the transcription factors, osteoblasts also exhibit differential gene expression
specific for the developmental stage. During preosteoblast proliferation, genes required
for the activation of proliferation (e.g. c-Fos, c-Jun, and c-Myc) and cell cycle
progression (e.g., histones and cyclines) are expressed along with the expression of genes
encoding growth factors (fibroblast growth factor [FGF], insulin-like growth factor-1
[IGF-1], transforming growth factor [TGF]), BMPs, cell adhesion proteins (e.g.,
fibronectin) and COL1 (Feldman, 2013).
Following the initial proliferation, a second stage of gene expression is associated with
the maturation and organization of the bone extracellular matrix (ECM). During this
stage, collagen synthesis continues and undergoes cross-link maturation. Genes
responsible for rendering the extracellular matrix competent for mineralization (e.g. ALP)
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are also up-regulated (Feldman, 2013). ALP hydrolyzes ester bonds in organic phosphate
compounds under alkaline conditions and is crucial in bone calcification (Anderson,
1989). As such, high ALP activity correlates to extracellular matrix formation in
osteoblasts before initiation of mineralization (Gerstenfeld et al., 1987).
Signals for the third stage involve down-regulation of genes involved in proliferation as
well as gene expression related to the accumulation of HA in the ECM. Genes encoding
non-collagenous

proteins

with

mineral-binding properties

(osteopontin

(OPN),

osteocalcin (OCN) and bone sialoprotein (BSP)) exhibit maximal expression during
matrix mineralization (Feldman, 2013). BSP is a glycosylated and sulfated
phosphoprotein found almost exclusively in mineralized connective tissues. During bone
formation, BSP becomes the nucleus for HA formation (Hunter and Goldberg, 1993).
OPN is a highly phosphorylated protein which is a prominent component of the
mineralized matrix (Oldberg et al., 1986). OCN is the most abundant non-collagenous
protein expressed preferentially by osteoblasts and can bine to calcium ions (Boivin et al.,
1990; Wolf, 1996). Active mature osteoblasts then secrete type I collagen and other
matrix proteins towards the bone formation surface (Clarke, 2008).
As a row of active osteoblasts secretes unmineralized matrix (osteoid) and advances away
from the bone surface, a small number of cells fall behind and become incorporated into
the matrix (Clarke, 2008). These osteoblasts begin to generate cytoplasmic processes and
become an immature osteocyte. As the matrix matures and mineralizes, the osteocyte
begins to mature and express a new set of genes, including those that encode dentin
matrix protein-1 (Dmp1), matrix extracellular phosphoglycoprotein (Mepe), and
sclerostin (Sost) (Feng et al., 2003; Nampei et al., 2004).
Finally, in mature mineralized cultures, collagenases are elevated, apoptotic activity
occurs, and compensatory proliferative activity is evident. This stage appears to serve as
editing/remodeling function for modifications in the ECM (Feldman, 2013). At the
completion of bone formation, 50 - 70% of osteoblasts undergo apoptosis, with the
balance becoming osteocytes or bone-lining cells (Clarke, 2008).
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1.2.2

Osteoclasts

In contrast to osteoblasts, osteoclasts form by the fusion of mononucleated precursors of
the monocyte/macrophage lineage derived from hematopoietic origins (Boyle et al.,
2003; Teitelbaum and Ross, 2003). The main function of osteoclasts is bone resorption.
Receptor activator of NF-kappa B ligand (RANKL) is critical for osteoclast formation
while macrophage-colony stimulating factor (M-CSF) is required for the proliferation,
survival, and differentiation of osteoclast precursors, as well as osteoclast survival and
cytoskeletal rearrangement required for bone resorption. RANKL and M-CSF are
produced in both membrane-bound and soluble forms mainly by marrow stromal cells
and osteoblasts (Boyce and Xing, 2008; Boyle et al., 2003; Ross, 2006). Osteoprotegerin
(OPG), also produced by stromal cells and osteoblasts, is a decoy protein that occupies
RANKL binding sites with high affinity to inhibit its action at the RANK receptor (Boyce
and Xing, 2008; Boyle et al., 2003). OPG action on osteoclast precursors and mature
osteoclasts prevents new osteoclast generation and induces apoptosis in existing
osteoclasts.

Hence,

the

ratio

of

RANKL

and

OPG

ultimately

determines

osteoclastogenesis (i.e. higher RANKL:OPG ratio leads to more activation of the RANK
receptor and osteoclast maturation) (Blair and Athanasou, 2004).
Osteoclasts are characterized by the presence of multiple nuclei, abundant mitochondria
an extensive Golgi apparatus, and numerous vesicles filled with lysosomal enzymes and
vacuoles containing acid phosphatase. The most prominent feature of an actively
resorbing osteoclast is its ruffled border with deep plasma membrane folds in the region
in contact with the bone matrix (Baron, 2003). Active osteoclasts create an acidic
microenvironment within this region via secretion of hydrogen ions to dissolve bone
minerals, while secreting various protease and other hydrolases such as cathepsin K to
degrade the organic matrix which is mostly composed of type I collagen (Novack and
Teitelbaum, 2008).
1.2.3

Osteocytes

Osteocytes are terminally differentiated osteoblasts that support bone structure and
metabolism (Clarke, 2008). Their function is poorly understood but have been implicated
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in mechanosensation, transducing stress signals from bending or stretching of bone into
biologic activity of other bone cells (Rubin and Lanyon, 1987). Flow of canalicular fluid
in response to external forces induces a variety of responses within osteocytes
(Bonewald, 1999). Rapid fluxes of bone calcium across filipodial gap junctions are
believed to stimulate transmission of information between osteoblasts on the bone surface
and osteocytes within the bone (Plotkin, 2011).
1.3

Bone Remodeling

The structural integrity and functionality of bone are maintained throughout life by
remodeling, a process that involves the coordinated resorption of old or damaged bone
and its replacement with newly mineralized bone matrix. Bone remodeling also plays an
important role in maintaining plasma calcium homeostasis (Clarke, 2008). A coordinated
balance between osteoclastic bone resorption and osteoblastic bone formation is essential
for a healthy and functional skeleton. Under physiological conditions, resorption and
formation are tightly coupled, and any imbalance to this process results in a variety of
skeletal disorders such as osteoporosis and inflammatory diseases including rheumatoid
arthritis and periodontitis (Novack and Teitelbaum, 2008). Bone remodeling is also
particularly relevant in orthodontic tooth movement as it is a prerequisite for tooth
movement to occur.
The bone remodeling cycle consists of four consecutive phases: activation of osteoclast
precursors; resorption, during which osteoclasts digest old bone (2 – 4 week); reversal,
when mononuclear cells appear on the bone surface; and formation, when osteoblasts lay
down new bone until the resorbed bone is replaced (4 – 6 months) (Baron, 2003; Clarke,
2008). (Figure 2) The regulation of bone remodeling is both systemic and local. The
major systemic regulators include parathyroid hormone (PTH), calcitriol, calcitonin and
other hormones such as growth hormone, glucocorticoids, and sex hormones. Factors
such as insulin-like growth factors (IGFs), prostaglandins (PGs), tumor growth factor-
(TGF-), bone morphogenetic proteins (BMPs), and cytokines are involved as well (Blair
and

Athanasou,

2004;

Boyle

et

al.,

2003).

Furthermore,

through

the

RANK/RANKL/OPG system, the processes of bone resorption and formation are tightly
coupled allowing bone formation to follow each cycle of bone resorption.

10

Bone homeostasis is maintained by differential gene expression in bone cells mediated by
a specific stimulus mentioned above. Each of these stimuli activates specific intracellular
signalling pathways that have been implicated in bone remodeling. Exogenous signals are
recognized by cellular receptors found on the cell membrane. Cell membrane receptors
are then activated and transfer the information across the cell’s cytoplasm to the nucleus
through a cascade of intracellular signaling events that involve a complex set of
transduction mechanisms. Intracellular receptors bind the stimulus and then translocate
that effector to the nucleus where the receptor agonist complex binds to a specific DNA
promotor sequence of a gene resulting in the expression of a specific gene.
Signaling pathways implicated in bone formation thus far are: adenosine 3’,5’-cyclic
monophosphate (cAMP)/protein kinase A (PKA) and MAPK; Wnt/-catenin;
Ca2+/NFAT; and PI3K/AKT signaling pathway (Greenblatt et al., 2013; Marie, 2002;
Soltanoff et al., 2009). Only the signaling pathways pertinent to this thesis are discussed
in the following section.
Ca2+/NFAT signaling pathway involves stimulation of specific receptors that result in
elevations of cytosolic Ca2+. This in turn activates calcineurin, an enzyme that
dephosphorylates NFATc1-4 transcription factors leading to their nuclear translocation
and transcriptional activation (Hogan et al., 2003; Macian, 2005; Rao et al., 1997).
Ca2+/NFAT pathway has been shown to regulate osteoclastogenesis (Boyle et al., 2003;
Novack and Teitelbaum, 2008; Teitelbaum and Ross, 2003) and play important roles in
regulation of osteoblast proliferation, differentiation and function (Koga et al., 2005; Sun
et al., 2005).
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Figure 2. Bone Remodeling by osteoblasts and osteoclasts
Bone remodeling is a process that involves the removal of old bone by osteoclasts and its
replacement by osteoblasts. It occurs in four phases: activation, resorption, reversal and
formation. In response to localized damage to the bone matrix or the actions of systemic
hormones, factors are released from osteoblast lineage cells resulting in recruitment of
monocyte/macrophage precursors to the bone surface. Differentiation of these precursors
leads to formation of a mature osteoclast characterized by its attachment to the bone
surface and formation of a specialized apical membrane structure termed the ruffled
border. Transport of protons and secretion of hydrolytic enzymes across the ruffledborder membrane causes dissolution of bone mineral and degradation of the organic
matrix. The activation and resorption phases take ~3 weeks to complete, and end with
death of the osteoclast by apoptosis. During reversal, factors released either from the
bone matrix or directly by the osteoclast lead to recruitment and proliferation of
mesenchymal progenitor cells at the site of resorbed bone which then differentiate to
form osteoblasts. Over the next 3 - 4 months, osteoblasts form bone through secretion of
an organic matrix composed primarily of collagen type 1 (COL1), termed osteoid, and
regulate its subsequent mineralization. During this process, a number of osteoblasts
become embedded within the matrix and terminally differentiate into osteocytes, the most
abundant cell-type in bone. (Figure courtesy of Dr. M.W. Grol; PhD Thesis (2013))
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The Wnt/-catenin-dependent canonical signaling pathway also plays an important role
in bone formation and remodeling (Robinson et al., 2006). It up-regulates the expression
of genes which induce the differentiation and maturation of osteoblast precursor cells and
induces an increase in the OPG:RANKL ratio, thus inhibiting osteoclastogenesis (Issack
et al., 2008; Kobayashi and Takahashi, 2008; Kubota et al., 2009).
2

Mechanotransduction in Bone and Orthodontic Tooth Movement

2.1

Mechanotransduction

Mechanotransduction refers to the process by which external mechanical stimuli is
translated into biological response. The skeleton remodels in response to physical forces
(Wolff’s Law) and this process is thought to depend on the detection of mechanical
deformation or fluid-shear by osteocytes (Wolff, 1892). Mechanical loading is considered
a particularly potent stimulus in eliciting bone remodeling and ultimately leads to a
localized increase in the rate of bone remodeling (Robling et al., 2006). While the exact
mechanism underlying mechanotransduction is poorly understood, mechanical loadinduced strains in the cells and in their extracellular matrix and stresses of fluid flow can
mediate changes in gene expression (Robling et al., 2006). When bone is mechanically
loaded, bending causes fluid movement in the canalicular network, which leads to shear
stress on integrin and actin molecules on the cell surface of osteocytes (Robling et al.,
2006). Fluid shear stimulates Adenosine 5-triphosphate (ATP) release which then binds
to cell-surface purinergic receptors to trigger a cascade of downstream signaling
pathways that ultimately culminates in initiation of osteoclastogenesis and differentiation
of osteogenic cells thus promoting bone formation and remodeling (Robling et al., 2006).
Skeletal mechanotransduction makes orthodontic tooth movement possible. Applied
orthodontic forces are transmitted to local cells in the periodontal ligament and alveolar
bone, stimulating the cells to release secondary signaling molecules that induce proinflammatory, angiogenic, and osteogenic properties as described in the previous
sections. These, in turn, trigger the process of remodeling of the periodontal ligament and
adjacent alveolar bone via gene expression. There is now conclusive evidence that
mechanotransduction is mediated by nucleotide release and subsequent purinergic
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receptor signaling in bone (Dixon and Sims, 2000; Robling et al., 2006) and this may
have important implications for OTM.
2.2

Link between Mechanical Stimulation, Nucleotide Signaling and Bone Formation

ATP is present in the cytoplasm of mammalian cells at concentrations of 2 - 5 mM
(Orriss et al., 2010). ATP has long been recognized as an intracellular energy source, but
it also plays an important regulatory role in a variety of biological processes. ATP is
released from cells constitutively and in response to mechanical stimulation, osmotic
swelling, shear stress and inflammation (Bodin and Burnstock, 2001; Burnstock, 2007),
and is thought to be a key mediator in skeletal cell responses to mechanical stimuli
(Dixon and Sims, 2000; Lenertz et al., 2011; Panupinthu et al., 2008; Robling et al.,
2006; Robling and Turner, 2009). Smaller amounts are released during neurotransmission
and paracrine signalling, while massive amounts are released in response to trauma and
cell lysis (Burnstock, 2007). ATP released from stimulated cells trigger intracellular Ca2+
increases within 1 minute after mechanical loading (Genetos et al., 2005). ATP release
from osteoblasts in vivo has been reported to range from 1-100 M (Orriss et al., 2009).
Following its release, ATP can act as an extracellular signaling molecule via interactions
with specific purinergic receptors to mediate a wide variety of processes. These processes
include neurotransmission (Edwards et al., 1992), inflammation (Perregaux and Gabel,
1994), stimulation of secretion (Chan et al., 1995; Chander et al., 1995), regulation of cell
proliferation (Weihs et al., 2014), induction of apoptosis (Chow et al., 1997), and bone
remodeling (Jones et al., 1997; Morrison et al., 1998). Subsequently, other second
messengers such as PGE2 (Rawlinson et al., 1991; Reich et al., 1997) and nitric oxide
(NO) (Rawlinson et al., 1996) are released from the mechanically stimulated cells and
lead to the induction of MAP-kinase signaling (ERK1/2) and c-Fos expression (Bowler et
al., 1999; Jessop et al., 2002; Lean et al., 1996).
It is now widely accepted that nucleotides released by cells in response to mechanical
stimuli act in an autocrine or paracrine fashion to regulate osteoblast and osteoclast
function by binding to cell surface purinergic receptors (Buckley et al., 2003; Genetos et
al., 2005; Orriss et al., 2009; Romanello et al., 2005). As such, ATP and purinergic
receptors are important modulators of both osteoblast and osteoclast activity and hence
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the bone remodeling process. The nucleotide induced signaling may help explain the
physiological responses of skeletal tissues to mechanical stimuli.
3

Purinergic Receptors

Extracellular ATP acts through binding to specific receptors on the cell surface called
purinergic receptors. Purinergic receptors are a family of cell surface receptors activated
by purines and pyrimidines (ATP, ADP, UTP, UDP, UDP-glucose) and are classified into
P1, P2X and P2Y subclasses (Burnstock, 1976; Fredholm et al., 1997). P1 receptors are a
family of G protein-coupled receptors activated by extracellular adenosine. P2 receptors
are activated by nucleotides and are subdivided into two classes: P2X (ATP-gated cation
channels) and P2Y (G protein-coupled receptors) (Burnstock, 2007).
3.1

P2 Receptors

P2 receptors play important roles in regulating cellular physiology and pathology and are
implicated in bone remodeling. In mammals, eight P2Y receptor subtypes are known
(P2Y1, 2, 4, 6, 11-14) whereas seven members of the P2X family (P2X1-7) are known to
exist (Burnstock, 2007). They are present in a variety of cell types, including osteoblasts
and osteoclasts (Burnstock, 2004; Dixon and Sims, 2000; Lenertz et al., 2011; Orriss et
al., 2010). In bone, ATP released by mechanical stress (Romanello et al., 2005) binds to
P2 receptors on cells of the osteoblast and osteoclast lineages, resulting in remodeling
(Buckley et al., 2003; Dixon and Sims, 2000; Lenertz et al., 2011)
The P2X family of receptors are ligand-gated ion channels permeable to Na+, K+, and
Ca2+ (Khakh and North, 2006). P2X receptor channels are formed by three subunits,
assembled either as homo- or heterotrimers. Binding of ATP to a P2X receptor causes a
conformational change in the shape of the receptor, which results in pore formation and
membrane depolarization. Each P2X subunit possesses intracellular carboxyl and amino
termini containing consensus binding motifs, transmembrane domains that line the ion
pore; and a large extracellular loop that participates in ATP binding (Burnstock, 2007).
3.2

P2X7 Receptors

Among the P2X subclass of receptors, the P2X7 receptor is unique in its molecular
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structure, expression and function (Burnstock, 2007; Jacobson et al., 2002; North, 2002).
It is a 595 amino acid polypeptide with two transmembrane domains and a long
intracellular C-terminus compared to the other P2X receptors (Denlinger et al., 2001;
Surprenant et al., 1996). P2X7 receptors exhibit additional distinctive features from the
other P2X receptor family members. These include the requirement of relatively high
concentrations of ATP for activation (in the range of 1 mM as compared to < 100 M
required for other P2X receptors) and 10-30 times more potent activation by 2’,3’-O-(4benzoylbenzoyl)-ATP (BzATP) than by ATP itself (Bianchi et al., 1999; Surprenant et
al., 1996). Acute activation of P2X7 receptors via short exposure to ATP rapidly opens a
reversible non-selective cation channel within milliseconds allowing the influx of Ca2+,
Na+, and K+, while sustained activation leads to the formation of large pores that allow
permeation of hydrophilic molecules – up to 900 Da - within seconds (North, 2002). In
humans, the P2X7 gene is highly polymorphic and genetic differences within P2X7 affect
receptor pore formation and channel function.
P2X7 receptors are highly expressed on immune cells including glial cells, macrophages
and other antigen-presenting cells (Surprenant et al., 1996). The presence of P2X7
receptors on immune cells implicates them in immune function and inflammatory
responses. Moreover, P2X7 may affect neuronal cells by regulating the processing and
release of interleukin-1β (IL-1β), a key mediator in neurodegeneration, chronic
inflammation and chronic pain. Specifically, changes in the intracellular concentration of
potassium induce the release of IL-1β, whose active form is a potent pro-inflammatory
cytokine (Colomar et al., 2003). Active IL-1β induces a cascade of events including the
production of superoxide products (Parvathenani et al., 2003) and tumor necrosis factor α
(TNF-α) (Woolf et al., 1997), both of which have roles in generation or maintenance of
pain. The accumulation of intracellular calcium also leads to the release of chemical
mediators, such as PGE2 and IL-1α and β, all of which have been implicated in
inflammation and bone biology (Brough et al., 2003; Gudipaty et al., 2003; Li et al.,
2005).
Prolonged activation of P2X7 leads to the formation of large pores, which is followed by
cytoskeletal rearrangement such as membrane blebbing, leading eventually to cell death
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in immune cells. Considering the overall distribution of P2X7 receptors on proinflammatory cells and the functional properties of P2X7 receptors, it is not surprising
that many studies have been conducted to determine the role of P2X7 in inflammation.
Labasi et al. examined the response of the P2X7 knockout (KO) mice in a monoclonal
antibody-induced arthritis model and showed that arthritis severity was significantly
attenuated in P2X7 KO mice (Labasi et al., 2002). Moreover, another study by Chessell
et al. showed that P2X7-deficient animals did not develop symptoms of pain following a
standard induction of inflammatory status (Chessell et al., 2005). Recent findings such as
these implicate P2X7 in mediating inflammatory pain. As such, a search for selective
antagonists has been pursued by pharmaceutical companies.
3.3

P2X7 in Bone Cells

Expression of P2X7 receptors in osteoclasts and osteoblast in rodent and human cells has
been consistently reported in a number of publications (Buckley et al., 2003; Burnstock
and Verkhratsky, 2009; Gartland et al., 2001; Grol et al., 2009; Nakamura et al., 2000;
Orriss et al., 2006; Volonte et al., 2006). However, only a subpopulation of bone derived
and calvarial osteoblasts demonstrate a positive nucleotide response (Gartland et al.,
2001; Ke et al., 2003; Panupinthu et al., 2008), indicating a possible heterogeneous
expression of P2X7 in the cells (Agrawal and Gartland, 2015; Grol et al., 2009).
Growing evidence implicates P2X7 in the induction of osteogenic differentiation of
human MSCs (Sun et al., 2013). Sun and colleagues show that ATP release following
shockwave treatment led to downstream p38 MAPK activation and c-Fos, and c-Jun
mRNA transcription mediated by P2X7 (Sun et al., 2013). Moreover, shockwave-induced
differentiation of MSCs was significantly reduced by the targeted inhibition of P2X7
adding further evidence of a P2X7 mediated effect (Sun et al., 2013). In another study,
P2X7 was shown to enhance osteogenic differentiation and mineralization in bone
marrow-derived MSC cultures from postmenopausal women (Noronha-Matos et al.,
2014). In post-menopausal women, an impaired osteogenic commitment in ageing MSCs
is seen as compared to those from younger females. However, osteogenic differentiation
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Figure 3: Consequence of ATP stimulation of P2X7 receptors in osteoblasts vs.
osteoclasts
This general schematic indicates the potential roles for P2X7 receptor signaling in bone.
ATP and other nucleotides are released from cells of the osteoblast lineage in response to
mechanical stimuli. ATP released into the extracellular environment can act in an
autocrine and/or paracrine manner to signal through multiple cell-surface P2 receptors
subtypes on osteoblasts and osteoclasts, regulating bone remodeling. P2X7 activation in
osteoblasts have been shown to stimulate bone formation, whereas its activation in
osteoclasts induces apoptosis resulting in reduction in bone resorption. Thus, the P2X7
receptor may be part of a sophisticated mechanism modulating bone remodeling upon
mechanical loading. (Image reprinted with permission from Purinergic Signalling, Grol
et al., 2009; Appendix B)
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and mineralization in postmenopausal MSC cultures were restored by P2X7 activation
with BzATP (Noronha-Matos et al., 2014). These findings suggest that P2X7 may indeed
promote the differentiation of MSCs into mature osteoblasts, resulting in enhanced bone
formation.
Signaling pathways activated by P2X7 receptors have been extensively studied in several
cell types (Budagian et al., 2003; Burnstock, 2002; Donnelly-Roberts et al., 2004; Ferrari
et al., 1999; Gendron et al., 2003; Humphreys et al., 2000). Activation of P2X7 receptors
couples to production of the potent lipid mediator lysophosphatidic acid (LPA) in cells of
the osteoblast lineage, resulting in dynamic membrane blebbing and enhanced
osteogenesis (Panupinthu et al., 2007; Panupinthu et al., 2008). Activation of
phospholipase A2 (PLA2) by P2X7 receptors can also lead to synthesis of eicosanoids
such as prostaglandins via cyclooxygenase pathways. PLA2 releases arachidonic acid, the
main component of phospholipids of the cell membrane, which can then be metabolized
by 2 pathways - the cyclooxygenase pathway involving cyclooxygenase 1 (COX1) and
cyclooxygenase 2 (COX2) and the lipoxygenase pathway. COX1 is constitutively found
in almost all tissues and is tissue protective. COX2 is activated during inflammatory
processes occurring due to cell injury to produce prostaglandins in large amounts. The
end products of P2X7 activation, LPA and PGE2, have been implicated in
mechanotransduction induced by P2X7. However, much of the signalling pathways and
downstream events following P2X7 receptor activation in osteoblasts remain to be
elucidated.
3.4

P2X7 Expression and Polymorphisms in Humans

The P2X7 gene is located on chromosome 12q24.31, spanning 53 kb with 13 exons
(Buell et al., 1998). It is highly polymorphic with 40 identified single nucleotide
polymorphisms that, in some cases, lead to loss or gain of function mutations (Husted et
al., 2013; Wesselius et al., 2011; Wesselius et al., 2013b).
It is hypothesized that variability in the expression of the P2X7 receptor is an important
factor in the individual variation to applied orthodontic loads and may provide the key to
understanding why some individuals are more prone to external apical root resorption
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(Hartsfield, 2009; Viecilli et al., 2009b). Furthermore, loss-of-function polymorphisms in
the P2X7 receptor are associated with lower bone mineral density (Wesselius et al.,
2013a), accelerated bone loss (Gartland et al., 2012) and increased osteoporosis risk
(Grol et al., 2009; Husted et al., 2013; Jorgensen et al., 2012; Ohlendorff et al., 2007;
Wesselius et al., 2013a). More specifically, Ohlendorff et al. reported that 10-year
fracture incidence in postmenopausal women is significantly associated with the
Glu496Ala and Ile568Asn polymorphisms of the P2X7receptor (Ohlendorff et al., 2007).
The authors also show that the Glu496Ala polymorphism results in decreased
susceptibility of osteoclasts to ATP-induced apoptotic death. Impaired osteoclast
apoptosis may enhance overall bone resorption, consistent with the increase in facture
incidence and with the skeletal phenotype of the P2X7 KO mouse described by Ke and
colleagues (Ke et al., 2003).
3.5

P2X7 and Its Role in Mechanotransduction

The role of the P2X7 receptor in osteoblast function has been highly debated. Early
reports suggested that P2X7 receptor activation caused enhanced osteoblast apoptosis
(Gartland et al., 2001). On the other hand, more recent studies suggest that P2X7
stimulation leads to increased membrane blebbing and bone formation, possibly mediated
via increased production of lysophosphatidic acid (LPA) and prostaglandin E2 (PGE2)
(Li et al., 2005; Panupinthu et al., 2007; Panupinthu et al., 2008). Activation of P2X7
receptors by exogenous nucleotides in vitro has been shown to couple to production of
LPA and PGE2, resulting in increased osteoblast differentiation and matrix mineralization
(Li et al., 2005). The P2X7 receptor is also thought to mediate the ERK1/2 activation
caused by fluid shear stress in osteoblast-like cells (Liu et al., 2008).
Ke et al. analyzed the long bone skeletal phenotype of P2X7 knockout (KO) mice. In
femurs, it was observed that knockout animals had significant reduction in periosteal
circumference (bone diameter), but not in length (Ke et al., 2003). This indicates that
P2X7 has a role in regulating radial bone growth (periosteal bone formation) and
expansion of the bone marrow cavity, but not longitudinal bone growth. In addition,
femurs displayed significant reduction in cortical bone content and total bone content. In
tibias, trabecular bone displayed an increased number of osteoclasts and a significant
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reduction in mass (Ke et al., 2003). This result strongly suggests that the reduction in
trabecular bone mass was due to increased osteoclast-mediated resorption. In addition,
periosteal bone formation was significantly decreased (Ke et al., 2003).
Interestingly, the skeletal phenotype of a second P2X7 KO mouse model has been
described by Gartland and coworkers with contrasting findings (Gartland et al., 2003).
These mice showed no overt skeletal phenotype with the exception of thicker cortical
bones than wild-type controls. This discrepancy may be due to the presence of a splice
variant that escaped deletion in these P2X7 KO mice, resulting in tissue-specific
expression of functional P2X7 receptors in these KO mice models (Nicke et al., 2009).
Based on findings from the P2X7 KO mouse described by Ke and colleagues (which
have no functional P2X7 receptors), P2X7 receptors appear to be required for normal
skeletal growth and anabolic responses to mechanical stimulation as the balance between
bone formation and resorption seems to be affected in the knockout animals. Thus, the
absence of P2X7 receptor could result in a disturbance in the coordination of bone cell
activities (Li et al., 2005; Panupinthu et al., 2008).
3.6

Controversy Regarding P2X7 Function in Osteoblasts

Underlying mechanism of P2X7 activation in osteogenesis is still unclear. There are
contradicting evidence for the effects of P2X7 activation on osteoblast differentiation and
matrix mineralization in vitro. Previous studies in our lab have shown that P2X7
activation in rat calvaria-derived osteoblasts lead to osteoblast differentiation and bone
formation (Panupinthu et al., 2008). However, a recent study by Orriss et al. reported
inhibition of bone formation with P2X7 activation in osteoblasts derived from the same
source (Orriss et al., 2012; Orriss et al., 2013). Difference in the culture methodologies
between the two groups may explain the discrepancy. Upon investigation into the
experimental set-up, we noted a difference in the culture media used to cultivate the cells.
Orriss et al. added dexamethasone (10 M) in the growth media in an effort to encourage
osteoblast differentiation and bone formation. We believe that dexamethasone may be the
reason behind the conflicting findings between the two groups.
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4

Steroids and Bone

Corticosteroids are a class of chemicals that includes the steroid hormones produced in
the adrenal cortex as well as the synthetic analogues of these hormones. They are
involved in a wide range of physiological processes such as stress response, immune and
inflammatory response, carbohydrate and protein metabolism, regulation of blood
electrolyte levels and behavior (Loeb, 1976; Swartz and Dluhy, 1978).
Glucocorticoids such as cortisol control carbohydrate, fat and protein metabolism, and
are anti-inflammatory by preventing phospholipid release, decreasing eosinophil action
and a number of other mechanisms. Mineralocorticoids such as aldosterone control
electrolyte and water levels, mainly by promoting sodium retention in the kidney.
Dexamethasone and its derivatives are almost pure glucocorticoids while prednisone and
its derivatives have some mineralocorticoid action in addition to the glucocorticoid effect.
Dexamethasone is a synthetic corticosteroid with anti-inflammatory and immunemodulatory properties against many conditions. Synthetic glucocorticoids are therefore
used to treat diseases caused by an overactive immune system, such as rheumatic
arthritis, a number of skin diseases, severe allergies, asthma, and even in certain types of
cancers among others. They are also used as immunosuppressive medications after organ
transplantation. Their anti-inflammatory effect is based on the indirect blocking of PLA2
and the suppression of the synthesis of both COX1 and COX2 leading to inhibition of
prostaglandin and leukotriene synthesis (Coutinho and Chapman, 2011). Their
immunosuppressive action is due to the inhibition of interleukins and IFN- (Coutinho
and Chapman, 2011). In dentistry, a low dose of dexamethasone is orally administered to
patients before and after wisdom teeth extraction for reduction of post-operative swelling.
(Sortino and Cicciu, 2011).
Glucocorticoids exert their effects by binding to the glucocorticoid receptor (GR) in the
cytosol. When the glucocorticoids bind to GR, the primary mechanism of action is via
regulation of gene transcription. The activated GR complex up-regulates expression of
anti-inflammatory proteins in the nucleus and down-regulates the expression of proinflammatory proteins by preventing translocation of pro-inflammatory transcription
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factors from the cytosol into the nucleus (Rhen and Cidlowski, 2005). The GR is
expressed in almost every cell in several forms. It induces many different effects in
different part of the body, which renders glucocorticoid its pleiotropic effects including
many harmful side effects.
Long-term use of corticosteroids has been associated with a number of side effects such
as thrush, bone loss, cataracts, easy bruising or muscle weakness (Buchman, 2001). A
serious

adverse

effect

worth

noting

is

glucocorticoid-induced

osteoporosis.

Glucocorticoids are involved in bone physiology but the exact mechanism is unclear. It
has been shown that osteoblasts and osteoclasts express glucocorticoid receptors and this
expression is affected by pro-inflammatory factors such as IL-6 and IL-11 (Angeli et al.,
2002). Glucocorticoids increase bone resorption by stimulating osteoclastogenesis by
shifting the RANKL:OPG ratio (Hofbauer et al., 1999) and by stimulating collagenase 3
post-transcriptionally (Knauper et al., 1996). It has also been demonstrated that
glucocorticoids inhibit new bone formation by directly inhibiting intestinal calcium
absorption and indirectly affecting the level of sex hormones. Glucocorticoids have been
shown to reduce estrogen levels and increase parathyroid hormone levels in the blood
leading to decreased bone formation (Canalis and Delany, 2002). In addition, the
expressions of paracrine factors such as insulin-like growth factor (IGF-I) and growth
hormone are also influenced (Heck et al., 1997). The changes in hormone levels and
bioactive molecules closely associated with bone metabolism seem to result in a
disturbance in bone homeostasis.

Glucocorticoid induced inhibition of new bone

formation and stimulation of bone resorption leads to bone dysplasia such as osteoporosis
(Olney, 2009).
A few studies have looked at the effects of glucocorticoids and OTM. However, the
difference in the experimental design such as the animal model, dosages, induction
periods, and the relative anti-inflammatory activity of the glucocorticoids seem to create
discrepancy in the findings (Bartzela et al., 2009). In rabbits, cortisone administration
was shown to result in a significant increase in the rate of OTM. The relapse rate was also
faster in the treatment group as compared to the control (Ashcraft et al., 1992). In rats,
prednisolone was shown to have no significant effect on the rate of tooth movement
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while a similar study done with methylprednisolone show increase in the rate of tooth
movement (Ong et al., 2000). Kalia and colleagues looked at the response of rat alveolar
bone upon acute and chronic methylprednisolone administration with or without
orthodontic forces (Kalia et al., 2004). Acute corticosteroid treatment led to a reduction in
bone turnover but the rate of tooth movement was unaffected. In the chronic group, the
degree of resorption was doubled which led to an increased rate of tooth movement. The
authors conclude that with chronic glucocorticoid use, the rate of active tooth movement
is greater, however this results in unstable final tooth position (Kalia et al., 2004). They
suggest that it is possible to treat patients on corticosteroid therapy with some
adjustments. For patients with short-term administration of the drug, it may be best to
postpone orthodontic treatment until the chronic phase is over and the patient is off the
medication. If the patient is already undergoing orthodontics, appliance adjustments
should be kept at minimal and the appointments should be scheduled with longer
intervals as bone turnover will likely be delayed and OTM could take longer in the acute
phase of glucocorticoid therapy. For patients undergoing long-term drug therapy, the rate
of tooth movement will be increased and the orthodontic appliance can be controlled as
usual or more frequently. It may also be necessary to decrease the amount of force used.
Furthermore, once the patient is in the retention phase of orthodontic treatment, a more
rigorous retention protocol may be recommended (Kalia et al., 2004).
5

Rationale, Hypotheses and Objectives of the Research

Given the importance of purinergic signaling in osteoblast differentiation and function,
the objective of this project was to investigate the signal transduction pathways that
function downstream of P2X7 in cells of the osteoblast lineage. As described above, there
is a controversy regarding the consequences of P2X7 receptor activation in osteoblasts. In
this study, we investigated the downstream events that follow BzATP activation of P2X7,
specifically in gene expression. Considering the important role of P2X7 plays in skeletal
mechanotransduction, we hypothesized that P2X7 activation induces the expression of
anabolic genes involved in bone formation in osteoblasts. Furthermore, we hypothesized
that this anabolic effect of P2X7 on gene expression is inhibited by glucocorticoids. In
the present study, we assessed effects of the glucocorticoid dexamethasone (Figure 4).
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Target genes of interest are those implicated in osteogenesis such as transcription factors
responsible for osteoblast proliferation and differentiation as well as genes that encode
bone matrix proteins.
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Figure 4. Controversy regarding the consequences of P2X7 receptor activation in
osteoblasts
This general schematic summarizes the current controversy surrounding the exact role
P2X7 plays in osteoblast function and eventual bone formation. Left panel indicates the
findings from past lab members of Dr. Dixon’s laboratory. Observations from Dr.
Dixon’s lab have consistently shown stimulation of bone formation with ATP-induced
P2X7 activation in osteoblasts (Panupinthu et al., 2008; Grol et al., 2009). Right panel
shows the observations of a U.K. group led by Dr. Arnett. In contrast to the findings from
our lab, they have shown that ATP activation of P2X7 in osteoblasts leads to inhibition of
bone formation. Differences observed may be attributed to the differences in the culture
condition used by the two groups.
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MATERIALS AND METHODS
1

Materials and Solutions

α-Minimum essential medium (α-MEM), heat-inactivated fetal bovine serum (FBS),
antibiotic solution (10,000 U/ml penicillin, 10,000 mg/ml streptomycin, and 25 mg/ ml
amphotericin B), trypsin solution, Dulbecco’s phosphate buffered saline (DPBS) were
obtained from GIBCO (Life Technologies Inc., Burlington, ON, Canada). TRIzol reagent
and UltraPure distilled water (DNase/RNase-free) were obtained from Invitrogen (Life
Technologies). RNeasy Mini Kit was from QIAGEN (Toronto, ON, Canada). qScript
XLT One-Step RTqPCR Toughmix ROX was purchased from Quanta. Primers and
probes for Ptgs2 (COX2, Mm00478374_m1), Dmp1 (Mm01208363_m1), c-Fos
(Mm00487425_m1), Mepe (Mm_02525159_s1), Col1a1 (Mm00801666_g1), Bglap
(osteoclacin;

Mm03413826_mH),

c-Myc

(Mm00487804_m1),

Mmp9

(Mm00442991_m1), Alpl (alkaline phosphatase; Mm01187113_g1) and 18S rRNA were
obtained from Applied Biosystems (Life Technologies).

2’-3’-O-(4-benzoylbenzoyl)

adenosine 5’-triphosphate triethylammonium salt (BzATP) was obtained from SigmaAldrich (St. Louis, MO, USA).
2

Cell Culture

The MC3T3-E1 osteoblast precursor cell line (subclone 4) was obtained from the
American Type Culture Collection (Rockville, MD, USA). MC3T3-E1 cells were
subcultured twice weekly and maintained in α-MEM, supplemented with 10% FBS and
1% antibiotic antimycotic solution (culture medium) at 37C and 5% CO2.
3

RNA Isolation

Total RNA was extracted using TRIZOL® reagent (Invitrogen, Paisley, UK) and RNeasy
according

to

the

manufacturer's

instructions.

Total

RNA

was

quantified

spectrophotometrically by measuring absorbance at 260 nM. RNA was diluted to 25ng/l
in RNase free water, aliquoted and stored at −80 °C until amplification by Real-Time RTPCR.
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4

Real-Time RT-PCR Analyses

MC3T3-E1 cells (mouse calvarial preosteoblasts) were plated at a density of 1.5x104
cells/cm2 on Falcon 6-well plates in culture medium. After 2 days, cells were placed in
serum-free medium and incubated overnight. Select wells were pre-treated with
dexamethasone (100 nM) or vehicle (100% ethanol) overnight (Figure 5). On the day of
the experiment, cells were incubated with BzATP (300 M) or vehicle (divalent cation
free buffer, DCFB) for the indicated times and total RNA was isolated as mentioned
above. Real-time PCR was performed using the ABI Prism 7900 HT Sequence Detector
(PerkinElmer) with 15 l final reaction volumes containing 25 ng RNA sample, qScript
XLT One-Step RTqPCR Toughmix, and one of Ptgs2, c-Fos, Mepe, Dmp1, Col1a1,
Bglap, Mmp9, c-Myc, Alpl or 18S rRNA primers and probes. Reverse transcription was
performed at 50 ̊C for 10 min followed by 40 cycles of amplification at an annealing
temperature of 60 ̊C. Reactions for each sample were performed in triplicate. All samples
were normalized to 18S rRNA, and time zero or vehicle- treated controls using the deltadelta cycle threshold (DDCt) method.
5

Data Analysis and Statistical Analyses

Data are shown as means ± standard error of the mean (S.E.M) for the number (n) of
experiments indicated, each performed in triplicate. Differences among three or more
groups were evaluated by two-way analysis of variance (ANOVA) followed by a
Bonferroni post hoc multiple comparisons test. Differences were accepted as statistically
significant at p < 0.05. Data analysis was performed using GraphPad Prism 6.0
(GraphPad Software, San Diego, CA).
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Pretreatment with
Vehicle or Dexamethasone

Plate cells

Day 0

Day 1

Day 2

Vehicle or
BzATP

Day 3

Figure 5. Timeline of the experiments
MC3T3-E1 cells were plated at a density of 1.5x104 cells/cm2 in Falcon 6-well plates in
culture medium (day 0). After 2 days, cells were placed in serum-free medium and
incubated overnight with dexamethasone (100 nM) or vehicle (ethanol). On the day of the
experiment (day 3), cells were incubated with BzATP (300 M) or vehicle (DCFB) at
time 0 hours. Total RNA was then isolated using Trizol at 0, 0.5, 1, 3 and 6 hours.
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RESULTS
1

BzATP stimulation of Ptgs2 (COX2) was inhibited by dexamethasone

Ptgs2 is the gene that encodes prostaglandin-endoperoxide synthase 2 also known as
cyclooxygenase 2 (COX2), a critical enzyme for the synthesis of prostaglandin E2
(PGE2). Recent studies suggest that a number of effects of P2X7 receptor activation
during osteoblast mechanotransduction may be mediated via prostaglandins (PGs) such
as PGE2 (Li et al., 2005).
Changes in Ptgs2 (COX2) expression were examined in MC3T3-E1 cells following
treatment with vehicle (DCF Buffer) or BzATP (300 M) in the presence or absence of
dexamethasone (100 nM). As previously shown by our lab (Grol et al., 2013), BzATP
induced significant stimulation of Ptgs2 expression (120 ± 46 fold difference) as
compared to the vehicle-treated cells. Ptgs2 expression reached the peak at 1 h and
returned to basal levels by 6 h. Statistically significant differences were present between
vehicle treated cells vs BzATP treatment at 1 h and 3 h (p < 0.001 for both time points)
whereas dexamethasone alone had no effect on Ptgs2 expression (Figure 6).
Dexamethasone, however, significantly reduced BzATP induced Ptgs2 expression at 1h
and 3 h (P < 0.001 for both time points) (Figure 6).
2

BzATP stimulation of Dmp1 was completely inhibited by dexamethasone

Dmp1 encodes dentin matrix acidic phosphoprotein 1, which is found in the extracellular
matrix of bone, dentin and cementum as well as in other non-mineralized tissues (George
et al., 1993; MacDougall et al., 1998). Dmp1 has been shown to be critical for the
mineralization of bone and dentin (Feng et al., 2006). Bone cells such as osteocytes,
osteoblasts and hypertrophic chondrocytes express Dmp1 (Feng et al., 2003; Toyosawa et
al., 2012).
We report, for the first time, that BzATP stimulates Dmp1 expression, which peaked at 3
h post BzATP treatment with a maximum fold difference of 8.4 ± 2.9. Further, this was
statistically significant at 1 h and 3 h (p < 0.01; p < 0.001, respectively). Dexamethasone
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completely abolished the BzATP-induced Dmp1 expression (Figure 7; p < 0.01 for 1 h, p
< 0.001 for 3 h).
3

BzATP dramatically stimulated c-Fos with no inhibition by dexamethasone,
indicating specificity

c-Fos is an immediate early gene, whose activation can be linked to different signaling
cascades responsible for cell proliferation, differentiation and survival (Dixon and Sims,
2000). c-Fos plays a crucial role in regulating proliferation and differentiation of bone
and cartilage cells (Hipskind and Bilbe, 1998). Fos proteins are highly expressed in
osteoblast precursors, but their levels decline following the initial proliferation stage
(McCabe et al., 1995).
We confirmed a dramatic increase in c-Fos expression at an early time point (30 min)
with BzATP stimulation of P2X7 (Figure 8; p < 0.001 for 0.5 h and p < 0.001 for 1 h).
However, in contrast to the findings for Ptgs2 and Dmp1, dexamethasone did not inhibit
this stimulatory effect indicating specificity of dexamethasone action on the expression of
particular genes (Figure 8).
4

BzATP and dexamethasone did not affect Col1a1 expression

We also looked at Col1a1, which encodes collagen type 1 alpha 1 found in connective
tissues such as bone, tendon and skin. Throughout the 6-hour time course, there were no
significant effects of BzATP or dexamethasone on Col1a1 expression (Figure 9). The
same was found for the following genes: Bglap (encoding osteocalcin), Alpl, c-Myc, and
Mmp9. This does not rule out the possibility of late induction of these genes following
P2X7 activation since, in the present study, the time course was limited to 6 hours.
NB: Please refer to Appendix A for data presented as relative gene expression without
normalization as percentage of the maximum value.
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Figure 6: Dexamethasone suppresses P2X7-induced expression of Ptgs2
MC3T3-E1 cells were pretreated with vehicle or dexamethasone (100 nM) overnight and
then treated with vehicle or BzATP (300 μM) at time 0. Total RNA was isolated at the
indicated times. RT-PCR was performed to assess expression levels of Ptgs2. Data were
normalized to levels of 18S ribosomal RNA, and relative to values for vehicle-treated
cultures at time 0. Data are shown as percentages of the maximum value in each
individual experiment and are presented as means ± S.E.M. (n = 3 independent
experiments, each performed in triplicate). The mean maximum value (100%) for these 3
experiments was 120 ± 46 fold increase relative to vehicle-treated cultures at time 0.
Differences were evaluated by two-way analysis of variance followed by a Bonferroni
multiple comparisons test.  indicates significant difference from vehicle/vehicle at each
time point;  indicates significant effect of dexamethasone pretreatment (p < 0.05). The
following points were also significantly different than vehicle/vehicle at time 0 –
BzATP/vehicle at 1h and 3 hrs; BzATP/dexamethasone at 1h.
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Figure 7: BzATP stimulation of Dmp1 is completely inhibited by dexamethasone
MC3T3-E1 cells were pretreated with vehicle or dexamethasone (100 nM) overnight and
then treated with vehicle or BzATP (300 μM) at time 0. Total RNA was isolated at the
indicated times. RT-PCR was performed to assess expression levels of Dmp1. Data were
normalized to levels of 18S ribosomal RNA, and relative to values for vehicle-treated
cultures at time 0. Data are shown as percentages of the maximum value in each
individual experiment and are presented as means ± S.E.M. (n = 3 independent
experiments, each performed in triplicate). The mean maximum value (100%) for these 3
experiments was 8.4 ± 2.9 fold increase relative to vehicle-treated cultures at time 0.
Statistical analysis was performed as mentioned in methods.  indicates significant
differences between BzATP treatment and vehicle at each time point;  indicates
significant differences between BzATP treatment vs. BzATP + Dexamethasone
pretreatment. (p < 0.05). The following points were also significantly different than
vehicle/vehicle at time 0 – BzATP/vehicle at 1h and 3 hrs.
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Figure 8: BzATP stimulates c-Fos expression with no inhibition by dexamethasone
MC3T3-E1 cells were pretreated with vehicle or dexamethasone (100 nM) overnight and
then treated with vehicle or BzATP (300 μM) at time 0. Total RNA was isolated at the
indicated times. RT-PCR was performed to assess expression levels of c-Fos. Data were
normalized to levels of 18S ribosomal RNA, and relative to values for vehicle-treated
cultures at time 0. Data are shown as percentages of the maximum value in each
individual experiment and are presented as means ± S.E.M. (n = 3 independent
experiments, each performed in triplicate). The mean maximum value (100%) for these 3
experiments was 279 ± 48 fold increase relative to vehicle-treated cultures at time 0.
Statistical analysis was performed as mentioned in methods.  indicates significant
differences from vehicle at each time point; No significant differences between BzATP
treatment vs. BzATP + dexamethasone pretreatment was found. (p < 0.05). The
following points were also significantly different than vehicle/vehicle at time 0 –
BzATP/vehicle at 1h and 3 hrs; BzATP/dexamethasone at 1h and 3 hrs.
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Figure 9: BzATP and dexamethasone do not affect Col1a1 expression up to 6 hours
MC3T3-E1 cells were pretreated with vehicle or dexamethasone (100 nM) overnight and
then treated with vehicle or BzATP (300 μM) at time 0. Total RNA was isolated at the
indicated times. RT-PCR was performed to assess expression levels of Col1a1. Data were
normalized to levels of 18S ribosomal RNA, and relative to values for vehicle-treated
cultures at time 0. Data are shown relative gene expression and are presented as means ±
S.E.M. (n = 3 independent experiments, each performed in triplicate). Statistical analysis
was performed as mentioned in methods. No statistically significant differences were
found between the treatment groups.
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DISCUSSION
The P2X7 receptor plays a role in the regulation of osteogenesis and is required for a
proper skeletal response in mechanical loading. This has important implications in
orthodontics, as OTM is dependent on mechanotransduction within the alveolar bone.
The exact role P2X7 plays in osteoblast activation and function and hence osteogenesis
remains poorly understood. Currently, there is contradicting evidence for the effects of
P2X7 activation on osteoblast differentiation and bone formation in vitro. While Orriss et
al. showed inhibition of bone formation with P2X7 activation in rat calvarial osteoblasts
(Orriss et al., 2012), a previous study by our lab showed an opposite effect of increased
osteoblast differentiation and bone formation following P2X7 activation in the cell-line
derived from the same animal model (Panupinthu et al., 2008).
Orriss et al. attribute their findings to a P2 receptor-dependent and/or receptor
independent mechanism via hydrolysis of extracellular nucleotides to pyrophosphate, a
known inhibitor of mineralization (Orriss et al., 2012). In a follow up study, they further
strengthen their argument by showing that the negative effect of ATP on bone formation
was reversed with apyrase treatment (which breaks down ATP) (Orriss et al., 2013). This
suggests that nucleotide signaling via purinergic receptors may potentially induce an antiosteogenic mechanism (Orriss et al., 2013).
Results from our lab provide evidence of a possible coupling of P2X7 activation with
production of potent lipid mediators, which may have an osteogenic effect. Panupinthu et
al. show that P2X7 activation of osteoblast function may involve phospholipase D and
phospholipase A2 stimulation leading to the production of LPA and PGE2, which
contribute to enhanced osteogenesis (Panupinthu et al., 2007; Panupinthu et al., 2008).
LPA signaling involves Rho-associated kinase, which has established roles in driving
non-committed cells towards osteoblast lineage (McBeath et al., 2004). In addition, Grol
et al. showed that Ca2+ influx following P2X7 activation causes a sustained increase in
metabolic acid efflux (measurement of osteoblast cellular activity) dependent on glucose
and phosphatidylinositol 3-kinase activity (Grol et al., 2012). Furthermore, the ATP
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induced Ca2+ signalling in osteoblasts is dose and duration dependent and is transduced to
distinct cellular signals (Grol et al., 2013). Low concentrations of ATP (1 nM to 100 M)
act through P2Y receptors to elicit transient Ca2+-NFAT (nuclear factor of activated Tcells) signaling whereas high ATP concentrations (300 M to 10 mM) act through P2X7
to induce a more sustained Ca2+-NFAT signaling ultimately stimulating expression of
Ptgs2 (COX2) (Grol et al., 2013). This up-regulation of Ptgs2(COX2) may translate to an
increased production of PGE2.
Further evidence supporting positive role of P2X7 in osteoblasts include the observations
of reduced alkaline phosphatase activity in osteoblasts isolated from P2X7 KO rats
(Panupinthu et al., 2008), decreased periosteal bone formation in long bones of P2X7 KO
mice (Ke et al., 2003), and their reduced osteogenesis in response to mechanical loading
(Li et al., 2005). In addition, several polymorphisms in the P2X7 leading to reduced
function of the P2X7 are associated with increased risk of osteoporosis in humans
(Gartland et al., 2012; Jorgensen et al., 2012; Ohlendorff et al., 2007).
The discrepancy observed between the findings of Orriss et al. and our lab may be
attributed to the differences in the experimental set up. Upon review of the culture
conditions, we noted several differences: a) dexamethasone was added to the culture
media used by Orriss et al. due to that fact that glucocorticoids have been shown to be
osteogenic in vitro (Bellows et al., 1994) b) duration of culture period, and c) the age of
the animals at the time cells were isolated. Given the pleiotropic nature of glucocorticoid
action in bone, we suspect that dexamethasone may be the reason behind the
contradicting observations.
In this study, we examined the changes in gene expression triggered by BzATP activation
of endogenous P2X7 receptors in osteoblasts. Furthermore, we examined the effect
dexamethasone has on BzATP induced gene expression in an effort to clarify the
mechanism of action dexamethasone has on osteoblast differentiation and function.
Ptgs2 is the gene that encodes prostaglandin-endoperoxide synthase 2 also known as
cyclooxygenase 2 (COX2), a critical enzyme for the synthesis of prostaglandin E2
(PGE2). Recent studies suggest that a number of effects of P2X7 receptor activation
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during osteoblast mechanotransduction may be mediated via prostaglandins (PGs) such
as PGE2 (Li et al., 2005).
Prostaglandins are important mediators of mechanical stress (Blackwell et al., 2010).
Other stimulants such as growth factors (Platelet-derived growth factors [PDGF]),
hormones (parathyroid hormone [PTH]), and interleukins and other cytokines also induce
PGE2 production and affect bone remodeling and tooth movement (Blackwell et al.,
2010). Clinical and animal studies have demonstrated the role of PGs in modulating bone
remodeling by stimulating bone resorption and bone formation. PGs increase osteoclast
number as well as their capacity to form a ruffled border resulting in subsequent increase
in bone resorption (Klein, 1970). In orthodontics, orthodontic force application induces
the synthesis of PGs, which in turn stimulate osteoclastic bone resorption (Davidovitch et
al., 1988; Yamasaki et al., 1984). A local injection of PGs into the paradental tissues of
rodents resulted in an increase in osteoclast numbers (Yamasaki et al., 1984). Moreover,
a reduced rate of tooth movement was observed after the administration of indomethacin,
an anti-inflammatory agent which inhibits PG synthesis by blocking COX1 and COX2
(Chumbley and Tuncay, 1986). The exact mechanistic role of PGs in bone resorption is
not clear but it is thought to stimulate cells to produce cyclic adenosine monophosphate,
which is an important chemical messenger for bone resorption (Klein, 1970; Raisz and
Koolemans-Beynen, 1974). In osteoblastic cells, PGE2 stimulates their differentiation and
eventual new bone formation, coupling bone resorption in vitro (Blackwell et al., 2010).
Recent work from our lab has shown that Ca2+-NFAT signaling pathway stimulates
expression of Ptgs2 (COX2) downstream of the P2X7 receptor in osteoblasts within 3
hours of ATP treatment (Grol et al., 2013) further suggesting that PGE2 produced by the
activation of P2X7 may act as an autocrine factor for osteoblast activation.
Given the important role of COX2 and PGE2 in osteoblast differentiation and responses
to mechanical stimuli (Blackwell et al., 2010), we examined changes in Ptgs2 expression
following ATP activation of P2X7. We confirm that BzATP stimulation of P2X7 leads to
a significant increase in Ptgs2 expression at similar time points as observed in our
previous study (Grol et al., 2013). Furthermore, we show, for the first time, that BzATP
induced Ptgs2 expression is inhibited markedly by dexamethasone (Figure 6). This

38

inhibitory action of dexamethasone on Ptgs2 gene expression may help explain the
current controversy surrounding the exact role of P2X7 activation in osteoblasts.
Moreover, this may also help deduce the mechanism of action of glucocorticoids in bone
cells at a transcriptional level.
Interestingly, we show that dexamethasone’s inhibitory effect on Ptgs2 was incomplete
as there was evidence of some Ptgs2 expression. This may be explained by multiple
factors. First, the extent of inhibition may be dependent on the concentration of
dexamethasone in a dose-dependent manner. It is possible that we would see greater
inhibition with a dose larger than 100 nM as used in this study. Secondly, we cannot rule
out the involvement of other signaling pathways or other P2 receptors whose signaling
pathways may not be sensitive to dexamethasone.
Dmp1 gene encodes dentin matrix acidic phosphoprotein 1, an extracellular matrix
protein that belongs to the small integrin-binding ligand, N-linked glycoprotein
(SIBLING) family of proteins (Staines et al., 2012). Dentin matrix acidic phosphoprotein
1 is found in the extracellular matrix of bone, dentin and cementum as well as in other
non-mineralized tissues (George et al., 1993; MacDougall et al., 1998). Dmp1 is critical
for the mineralization of bone and dentin, as mutations in the gene are known to cause
autosomal recessive hypophosphatemia, which can manifest as rickets and osteomalacia
(Feng et al., 2006). In bone, Dmp1 is expressed in osteocytes, osteoblasts and
hypertrophic chondrocytes (Feng et al., 2003; Toyosawa et al., 2012).
In this study, a significant stimulation of Dmp1 expression with BzATP is also observed,
although not to the same fold difference as seen with Ptgs2 (120 ± 46 [Ptgs2] vs 8.4 ± 2.9
[Dmp1]), (Figure 7). Dmp1 expression peaks at a later time point than Ptgs2 which may
be due to the fact that the genes required for the matrix proteins are activated downstream
of Ptgs2. Interestingly, there was a complete inhibition of Dmp1 stimulation by
dexamethasone. In contrast to Ptgs2, the signaling pathway that leads to Dmp1
expression may be highly dependent on P2X7 and selectively inhibited by
dexamethasone.
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As mentioned briefly in the introduction, extracellular stimuli regulate gene expression
via the activation of intracellular signaling systems that transduce the signal from
membrane-bound receptors to transcription factors. This results in the rapid, transient
induction of genes known as “immediate early gene” whose products mediate the
appropriate cellular response. c-Fos is an example of an immediate early gene, whose
activation can be linked to different signaling cascades targeting distinct promoter
elements through the phosphorylation of transcription factors (Dixon and Sims, 2000).
Fos proteins are highly expressed in osteoblast precursors, but their levels decline
following the initial proliferation stage (McCabe et al., 1995).
c-Fos encodes a transcription factor which, as part of an activator protein 1 (AP-1)
complex, plays a crucial role in regulating proliferation and differentiation of bone and
cartilage cells (Hipskind and Bilbe, 1998). c-Fos induction plays an important role in
vitro in driving immortalized fibroblasts to enter the cell cycle and plays an important
role in vivo in the skeletal system (Bowler et al., 1999). Mice overexpressing c-Fos
develop osteosarcomas and chondrosarcomas, whereas mice lacking c-Fos fail to develop
osteoclasts and thus develop osteopetrosis in which the bone remodeling process
becomes shifted towards bone accumulation (David et al., 2005; Johnson et al., 1992;
Wang et al., 1992). These findings implicate that c-Fos plays a key role in the regulation
of skeletal cells. Accordingly, a number of proteins found in differentiating bone cells
have regulatory AP-1 sites in their promoters, and a variety of extracellular factors
involved in osteogenesis activate c-Fos transcription in cultured bone cells in vitro
(Evans, 1996; Hipskind and Bilbe, 1998).
It has previously been shown by our lab that extracellular ATP rapidly increases c-Fos
mRNA in UMR-106 osteoblastic cells at levels as low as 10 M via P2 receptors (Dixon
and Sims, 2000). It has also been shown that nucleotides potentiate the induction of c-Fos
expression by parathyroid hormone in the human osteoblast-like cell line SaOS-2 and in
primary human bone derived cells (Bowler et al., 1999).
In this study, we confirm the findings reported thus far and show that BzATP activation
of P2X7 receptors lead to a rapid and dramatic induction of c-Fos expression. Within 30
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minutes of BzATP treatment, we observed a 279 ± 48 fold increase in c-Fos expression
as compared to the vehicle treated cells. In contrast to the previous 2 genes presented,
dexamethasone does not significantly affect this stimulatory effect (Figure 8). This
further corroborates with our hypothesis that BzATP stimulation of P2X7 leads to an upregulation of osteogenic genes as c-Fos 1) promotes proliferation of osteoblasts and 2) as
a transcription factor, it may trigger downstream signaling events which may eventually
lead to up-regulation of various osteogenic genes. The finding that dexamethasone does
not have an inhibitory effect on c-Fos expression may be attributed to the specificity of
dexamethasone action. It is possible that dexamethasone only affects a specific set of
genes directly involved in osteoblast differentiation.
Additionally, we examined other transcription factors as well as genes that encode
various matrix proteins expressed during osteoblast differentiation. As mentioned in the
introduction, a series of transcriptional events control the commitment of mesenchymal
stem cells to a mature osteoblast. To summarize, RUNX2 is a key transcription factor
controlling osteoblast differentiation. Osterix (OSX) acts downstream of RUNX2 and is
specific for early and late stages of osteoblast differentiation (Koga et al., 2005;
Nakashima et al., 2002; Nishio et al., 2006). The combined expression of RUNX2 and
OSX initiates development of the committed preosteoblast which is characterized by
expression of COL1 and BSP. Subsequent induction of activating transcription factor 4
(ATF-4) together with OSX and various Wnt/-catenin signaling components leads to
development of the mature osteoblast which express COL1, alkaline phosphatase (ALP)
and osteocalcin (OCN) (Grol et al., 2009).
Type 1 collagen (COL1) is a major organic constituent of the extracellular matrix in
bone. Its main function is to provide scaffolding for the nucleation of hydroxyapatite
crystals during calcification. Non-collagenous proteins aid in the organization of the
collagen matrix and regulate the formation and growth of hydroxyapatite crystals.
Osteocalcin is the most abundant non-collagenous bone matrix protein (Wolf, 1996). It is
a small carboxyglutamate protein expressed preferentially by osteoblasts and can bind
calcium ions (Boivin et al., 1990). Alkaline phosphatase hydrolyzes ester bonds in
organic phosphate compounds under alkaline conditions and plays an important role in
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bone calcification (Anderson, 1989). Mmp9 encodes for matrix metalloproteinase 9
which is an enzyme responsible for degrading extracellular matrix in physiological and
pathological processes. It has been shown that RUNX2 mediates transactivation of the
Mmp9 promoter site in MC3T3-E1 cells (Pratap et al., 2005).
In this study, we show for the first time that neither BzATP nor dexamethasone affect the
expression of Col1a1, Bglap (encoding osteocalcin), Alpl and Mmp9 up to 6 hours
(Figure 9). This does not rule out the possibility of late induction of these genes following
P2X7 activation since the time course was limited to 6 hours in the present study. Genes
involved in matrix formation and maturation may be induced days following P2X7
activation. Indeed, a recent study by Kariya et al. show that tension-force induced P2X7
activation resulted in the up-regulation of RUNX2 and OSX in earlier time points (3 h
and 6 h respectively), while COL1 and BSP peaked at day 3 and day 7 respectively
(Kariya et al., 2015). Moreover, the expression of genes encoding downstream matrix
proteins expressed by mature osteoblasts, OPN, OCN and ALP, peaked on day 14 of
culture (Kariya et al., 2015). It would be informative to extend the time course and
observe the changes in the expression of matrix genes upon P2X7 activation.
We also looked at c-Myc, another regulator gene that codes for a transcription factor. The
protein encoded by the c-Myc gene is a multifunctional nuclear phosphoprotein that plays
a role in cell cycle progression, growth, differentiation and apoptosis. Similar to c-Fos, cMyc is also a proto-oncogene as its expression is often up-regulated in various forms of
cancer. c-Myc expression is activated upon various signaling pathways such as Wnt and
EGF (Ran et al., 1986; Zhang et al., 2012). It is also shown to be dependent on BMP
induced signaling as it was shown to increase in BMP induced osteogenesis (Piek et al.,
2010; Sakano et al., 1997). Here we showed that c-Myc expression was not affected by
either BzATP or dexamethasone up to 6 hours. This could be due to the possibility that cMyc expression may be dependent on a signaling pathway distinct from those activated
upon P2X7 activation.
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There are a few limitations of this study that should be noted.
a) Firstly, we used a mouse osteoblast precursor cell line. As there are inherent
species-specific differences between a mouse and human osteoblastic cell line,
this may translate to differences in molecular interactions in bone remodeling as
well.
b) Secondly, BzATP may not specifically activate P2X7 as it is known to also
stimulate other P2X receptors such as P2X1 with high affinity. Some of the
effects seen in the study may be a result of a compounded effect of P2X receptors.
c) Thirdly, it would have been helpful to have a control (time 0 hours) sample of
cells treated overnight with dexamethasone. During the optimization process, we
changed conditions from simultaneous treatment with dexamethasone and BzATP
to overnight pretreatment of dexamethasone. However, due to an oversight, time 0
samples for dexamethasone treatment groups were not collected. Thus, it is
possible that dexamethasone alone affects the expression of certain genes
irrespective of BzATP action. In such cases, we do not have the time 0 control
with which to compare changes in gene expression. However, this does not affect
our conclusions regarding the actions of dexamethasone on responses to BzATP.
In the future, a time 0 control for dexamethasone-treated cells should be included.
d) Lastly, findings in the calvaria bone cells may not be extended to the jaw bones as
bone characteristics may be site-specific (Judex et al., 2004). The differences
between the different bone types may translate to differences in bone
mechanotransduction. Viecilli et al studied the dentoalveolar morphology in WT
and P2X7 KO mice and found no statistically significant differences between the
two mouse types (Viecilli et al., 2009a). They conclude that P2X7 does not seem
to have a major effect on alveolar bone or tooth morphology and that its effects
may be site-specific to long bones. However, in a separate study published in the
same year by the same group, the role of the P2X7 in orthodontic mechanical
loading was investigated via P2X7 KO mouse model (Viecilli et al., 2009b). They
show that hyalinization and root and bone resorption were different in the 2 types
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of mice (increased in the KO mouse) and conclude that P2X7 plays a significant
role in orthodontic mechanotransduction (Viecilli et al., 2009b). Nevertheless,
there is a possibility that our findings may not be extrapolated to alveolar bones.

In conclusion, we show for the first time that dexamethasone inhibits osteogenic
activities in bone cells in response to mechanical stimulus. As we hypothesized, the
expression of anabolic genes such as Ptgs2 and Dmp1 are stimulated by BzATP
activation of the P2X7 receptor. However, this is inhibited by dexamethasone confirming
that dexamethasone may indeed have an inhibitory role in osteoblast differentiation and
activation and eventual bone formation (Figure 10). In contrast to Ptgs2 and Dmp1, the
expression of c-Fos is stimulated with BzATP but not significantly affected by
dexamethasone. This may indicate that dexamethasone specifically inhibits the
expression of particular genes. We examined various other genes involved in osteoblast
activation and bone formation and did not find a significant effect of BzATP stimulation
with these genes up to 6 hours. An extended time course performed in primary osteoblast
differentiation study is necessary to see if indeed these genes are regulated via P2X7
activation at later time points and whether dexamethasone has an effect.
It is also possible that while a transient activation of P2X7 is osteogenic, sustained
stimulation could inhibit osteoblast function and activity (Agrawal and Gartland, 2015).
It has been shown that, while short term application of BzATP induces reversible
membrane blebbing without the activation of the key apoptotic mediator caspase-3 in
murine osteoblastic cells (Li et al., 2005; Panupinthu et al., 2007), longer agonist stimulus
can cause extensive membrane blebbing and ultimately lead to apoptosis (Gartland et al.,
2001).
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Suggestions for Future Studies
a) An important follow up to this study would be to repeat the study with P2X7
specific antagonists. This will strengthen the argument that the effects seen here
were due to activation of P2X7 rather than other P2 receptors.
b) A differentiation study done in a primary osteoblast culture looking at a longer
timeline post ATP treatment should clarify whether the expression level of the
genes involved in matrix mineralization is affected.
c) Future work should also assess the amount of bone formation in primary rat or
mouse osteoblasts with BzATP treatment in the presence of absence of
dexamethasone. We hypothesize that an increased bone formation will be seen
with BzATP treatment and that dexamethasone will reverse these effects.
d) It would also be informative to measure the level of PGE2 in the cell supernatant
with an enzyme-linked immunosorbent assay (ELISA) to confirm the downstream
effects of BzATP induced COX2 expression.
e) Repeating this study with PGE2 and LPA receptor antagonist will help further
clarify the downstream signalling events following P2X7 activation and help
dissect the autocrine/paracrine mechanism of osteoblast activation.
f) It will be of interest to perform a dose dependent study with ATP as well as
dexamethasone. It is possible that downstream signaling events following ATPmediated P2X7 activation are dose and duration dependent (Grol et al., 2013).
Dexamethasone action may also vary depending on the dosage and the duration of
pre-treatment. We can vary the dose and the duration of dexamethasone pretreatment and study the effect on dexamethasone-induced inhibition of osteogenic
gene expression and bone formation.
g) Eventually, it will be helpful to reproduce this study in an animal model such as
mouse. We can treat P2X7 KO and wild type mice with or without
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dexamethasone treatment and observe the differences in bone remodeling upon
mechanical loading by studying the response in bone.
Last section of this thesis will briefly discuss the clinical relevance of the current findings
in orthodontics and bone physiology.
Relevance of the Study in Orthodontic Tooth Movement
There are few studies directly addressing the biological mechanisms underlying
mechanotransduction in orthodontics. In this study, we set out to elucidate molecular
interactions during bone remodeling occurring in orthodontic tooth movement in order to
better understand the relationship between genes and transcription factors implicated in
bone remodeling. Expanding our basic science knowledge of the underlying mechanisms
of OTM will help improve orthodontic mechanotherapy to be more biologic and efficient.
Any interference responsible for inhibiting or delaying the sequence of events following
mechanical stimulation leading to bone remodeling can have a negative effect on OTM.
Here we show that dexamethasone may inhibit osteoblast maturation and bone formation
via its inhibitory action on osteogenic gene expression. This finding may help explain
why patients who have been on long-term corticosteroid therapy may react differently to
orthodontic forces (Kalia et al., 2004). Initially, reduced bone formation may translate to
an increased rate of tooth movement during active orthodontic treatment but decrease
long-term stability during the retention phase. Hence, orthodontic patients on
corticosteroid therapy may be more prone to post-treatment relapse and it may be
necessary to implement a more stringent retention measures.
Relevance of the Study in Glucocorticoid-Induced Osteoporosis
Glucocorticoid-induced osteoporosis is a serious side effect of glucocorticoid therapy
which can lead to fractures in 30 - 50% of patients (Fraser and Adachi, 2009). The
mechanisms we have shown in this study may contribute to glucocorticoid-induced
osteoporosis as we show that up-regulation of certain osteogenic genes on mechanical
loading were inhibited by dexamethasone.
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Furthermore, we suspect that patients suffering from glucocorticoid-induced osteoporosis
may not respond favourably to exercise. Such patients may not react to mechanical
loading the same way a normal healthy individual would. As observed in the study by
Orriss et al, P2X7 activation in the presence of dexamethasone may trigger a distinct
signaling pathway leading to inhibition of bone formation causing an imbalance in bone
remodeling (Orriss et al., 2012; Orriss et al., 2013). Therefore, dexamethasone may
possibly worsen the condition by inhibiting osteogenesis and promoting bone resorption.
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SUMMARY AND CONCLUSIONS

•

We confirmed that the P2X7 agonist BzATP stimulates expression of Ptgs2 in
osteoblastic cells.

•

We show, for the first time, that BzATP stimulates expression of Dmp1.

•

We also show, for the first time, that BzATP stimulation of Ptgs2 (Cox2) and
Dmp1 expression is inhibited by dexamethasone.

•

BzATP dramatically stimulates c-Fos expression at early time points with no
inhibition by dexamethasone. This indicates that the inhibitory effects of
dexamethasone are specific for the expression of particular genes.

•

In contrast, neither BzATP nor dexamethasone significantly affects the expression
levels of Col1a1, c-Myc, Bglap, Alpl or Mmp9.

•

Consistent with our hypothesis, dexamethasone inhibits the ability of BzATP to
stimulate the expression of two anabolic genes (Ptgs2 and Dmp1) in osteoblastic
cells).
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Figure 10. Summary of the findings
We show for the first time that dexamethasone inhibits osteogenic activities in bone cells
in response to mechanical stimulus. We confirmed that the P2X7 agonist BzATP
stimulates expression of Ptgs2 and Dmp1 in osteoblastic cells. However, this is inhibited
by dexamethasone confirming that dexamethasone may indeed have an inhibitory role in
osteoblast differentiation and function, and eventual bone formation. In contrast to Ptgs2
and Dmp1, the expression of c-Fos is stimulated with BzATP but not significantly
affected by dexamethasone. This may indicate that dexamethasone specifically inhibits
the expression of particular genes.
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APPENDICES
Appendix A: Results presented without the normalization as percentage of
maximum gene expression.
Data are shown as relative gene expression of respective genes.
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